FDA approved Prozac for children notwithstanding its severe side-effects or unknown long-term prospects. But let us go back to late 2003, when the British drug regulatory body -the MHRA -decided to publish a reaction to the previous statement that turned heads in the media. After reviewing clinical trials that had been conducted in the 1990s, the message of the British watchdog on drug safety was clear: doctors were going to be prohibited to administer new-generation antidepressants to children and young adolescents on the island. However, the ban did not include the famous wonder-drug of the 1980s, Prozac.
In a statement of September 23, 2004 , Robert Temple -then-director of the Office of Medical Policy at the FDA -condemned Britain's decision. In his report, he calls this conclusion "premature" and a "disservice to the public health given the serious and potentially life-threatening nature of severe depression". 20 That is, the FDA justified the approval by stating that "there are no acceptable therapeutic alternatives for health care providers and their pediatric patients with depression" (ibid.) and concluded that it would be more reasonable to prescribe a drug with serious side-effects than none at all. 
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This line of reasoning came to represent the general position of the FDA in the Prozacdebate, according to which the risks of untreated depression were greater than possible physical long-term damage caused by antidepressants. Only a few months earlier, at the end of March, the FDA had issued a public document stating that the regulator "has not concluded that these drugs cause worsening depression or suicidality". If we imagine a random patient reading these lines, he would most likely conclude that research had not shown these side-effects to occur frequently; he would believe that the warning is just a sensitive precaution on behalf of the FDA. However, in contrast with that, the statement simply -and probably intentionally -omits very important information: the FDA could not conclude that Prozac caused these side-effects for the simple reason that it had not conducted any prior studies on it. Therefore, we can conclude that the warning is highly misleading for any individual seeking information about the drug, and also for parental guardians who are making a decision on behalf of their children.
Children and adolescents on the European continent were next when the Swedish Medical Products Agency (MPA) entered the debate. In its comment on an assessment report dating April 2005, the regulator confirmed that there were some very serious concerns with regard to side-effects, but basically agreed that Prozac should be approved "provided commitments of further studies". This time, the explanation for recommending the approval of Prozac hinted at the fact "that SSRIs, including fluoxetine, are used 'off label' in children and adolescents, and approving its use allows for providing treatment recommendations, better post marketing surveillance in these populations and possibilities to request further studies" (p. 1). 21 In short: children should, so the MPA, be given
Prozac not because research on adverse effects could be done only after administering it to the pediatric population, and hence after seeing what long-term side-effects young patients naturally would experience. straightforward: it claimed that administration of Prozac to the young population not only increased suicidal behavior, but that it also had adverse long-term effects on sexual, cognitive, and emotional development. The statement opens by saying that "it is not recommended to grand an indication to fluoxetine for the treatment of depression in children and adolescents because the benefit/risk balance in the claimed indication is deemed negative" (p. 34). Apart from the clinical concerns, the Board raised some questions about the research methodology that had been employed to prove any beneficial effect of Prozac, revealing another transparency gap that the company had been trying to conceal.
Upon closer examination of test data, the CBG had found that "the patients population […] included in the trials [was] a highly selected group [and ] not likely to be representative of the total depressed patient population" (p. 9). That is, the results of the test trials that the FDA had used to justify the approval were . Furthermore, we have to keep in mind that "also non-significant increases […] might represent a serious risk" (p. 11). As a perfect example of incorrect studies, it is needless to say that this directly goes against our definition of transparency. It is highly likely that the regulator chose to proceed behind closed doors in order to push through a dubious drug for the treatment of the pediatric population, which had -under strict medical and scientific standards -been impossible. In the light of all these concerns, the Dutch Evaluation Board urged the FDA to conduct more accurate research projects. And the latter declined.
The FDA rejected to conduct studies on adverse-effects on several grounds. First, it argued that it would be difficult -if not impossible -to study long-term implications of Prozac on sexual maturation in humans. They stated that such a study would be "unacceptable to patients, parents and investigators and [would] not likely to be approved by ethical review boards" (ibid., p. 12). Second, the FDA found that, "due to the negative publicity about SSRls, the company now foresaw recruitment problems and claimed that it would be unrealistic to expect that the study could be finalized within the requested time frame" (p. 11). Instead, the FDA released data of some retrospective studies. Unfortunately, the Dutch Medicines Evaluation Board concluded that "the results of this study [were] not presented", and that some "results from the company's adverse event data-base [were in fact] presented but rendered as inconclusive" (p. 8). In general, we can infer that the FDA tried to somehow circumvent the possibility of any release of data that would prove the drug's risk for the pediatric population. Therefore, the CBG concluded that "the responses do not provide any assurance that these issues will be explored in the future by the company" In light of all these issues, we would naturally expect additional clinical trials to be conducted in order to shed light on the matter at hand. We would assume that those regulators arguing in favor of the approval of Prozac would conform to the reasonable opinion of the majority, the Rapporteur's opinion to weigh heavier than superficial arguments, and that there would be a serious attempt to protect children who are too young to make autonomous decisions about alternative treatment methods. But none of this ever happened.
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The first of June, 2006 turned out to be a historical moment in the history of psychopharmacology and for the general debate about transparency in the health sector. Notwithstanding previous concerns of several European member states, the EMA suddenly approved the use of Prozac for depressed children and adolescents aged 8 to 17 years. A Question and Answer Sheet accompanied the decision. Here, it states that the Committee for Medicinal Products for Human Use (CHMP) "gave a positive opinion to extend its use in the treatment of children suffering from depression, provided that the marketing authorization holder (MAH), Eli Lilly, carries out additional studies to ensure that the safety profile of Prozac remains acceptable". 25 In short: Prozac was unexpectedly approved for the psychiatric treatment of the pediatric population given the condition that follow-up studies on risks and side-effects would be conducted in the future; studies that had, in the few months before, been rejected by Lilly due to reasons mentioned above.
The EMA soon came up with an explanation: the data that led to the decision to approve Prozac for the treatment of young people had been extracted from different sources, including databases and scientific journals. The conclusions are surprising: while "the studies in children and adolescents showed a positive effect", they acknowledged
that "doctors and parents should carefully monitor [them] for suicidal behavior" (ibid.).
They concluded that the "benefits of Prozac are greater than its potential risks for the treatment of moderate to severe major depressive episode in children and adolescents"; is to "establish a clinical register, but it is important that it should be independent" (p.
5). Furthermore, as we have seen, the latter is especially important as post-licensing regulations can grant drug-regulators time -a buffer so to say -in which simply no research is being conducted.
If we were able to abolish some of the corruption in the FDA and thereby increase transparency, other regulators could function independently as well -improved transparency in the FDA might lead to a 'spill-over' effect, eventually spreading to the scientific community, which would then have a bigger voice in decision-making processes and could serve as an advisory body for various drug-regulators. Additionally, we need to strengthen the ties between research and the government: the latter should not only promote research into adverse effects of drugs, but also "into the costs of drug-induced illness". The government should have the authority to issue safety warnings on drugs that are rendered harmful. Fung and his colleagues (2007) add that "the government can help reduce those risks or improve services by stepping in to require the disclosure of missing information" (p. 6).
In the light of the incredible numbers of people falling prey to marketing strategies of drug companies, it also seems necessary to reconsider the role of drug advertisement, which can mislead patients and healthy individuals. In line with this, Fung states that the aggressive promotion of medicines shortly after launch [...] and the promotional hospitality masquerading as education, in the absence of effective countervailing forces, all contribute to the inappropriate prescription of medicines (p. 7).
Medication does not, and should never be thought to, fall into the same category with other goods we purchase in our daily life, and hence it should not be treated as such.
The government needs to perform regular checks and balances to planned marketing campaigns. Although this problem concerns the situation in America much more urgently, pre-cautious measures should be taken on European soil as well. Hence, Fung argues that transparency necessarily has to include "mandated public disclosure by corporations or other private or public organizations of standardized, comparable, and disaggregated information regarding specific products" (p. 8). I line with this, some have forcefully stated that "we need an industry which is led by the values of its scientists, not those of its marketing force" (p. 6). Yet we cannot simply assume that transparency is merely about the amount of information made available to the public. Instead of overwhelming the patient with data, the promotion of transparency calls for careful moves; otherwise, "infusing a flood of information on the public can cause disruption and misunderstanding", 39 thereby rendering patients immune to the idea of investigating on their own medical conditions.
All in all, the undertaking to achieve a higher degree of transparency will "require crosssector collaboration that is unprecedented in even the most advanced health systems" (p. 90). Before we can implement concrete changes, so it seems, main stakeholders in the pharmaceutical industry and scientific community need to change their mindset. As
Transparency International states, "health is a major global industry, a key responsibility and budget expense for governments and businesses; but more than that, it is a global human right". 40 And it is beyond question it deserves to be treated like that.
Discussion and Conclusion
This essay focused on a case-study that illustrates the lack of transparency that, unfortunately, has become an indistinguishable feature of the health sector. 
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some general recommendations on how to do so. These included, amongst others, the disentanglement of drug companies from regulatory bodies, physicians and the scientific community, accompanied by more autonomy for the latter. Moreover, an independent database on clinical trials and side-effects is desirable, as well as a bigger role for the government. Implementing concrete changes in the relevant instances will only be the first step, however. In the long run, we are facing the challenge of moving away from the idea that every disorder necessarily has to be treated with medication. Long lingering beneath the surface of the companies, economic benefit can no longer precede ethical considerations. Children and adolescents deserve careful assessments, tight monitoring, and a sincere will to contribute to their normal development -all of which do, to a significant extent, concern the pharmaceutical industry. Undoubtedly, there is still a long way to go if we sincerely want to limit the pharmaceutical industry in their range of influence. Eventually, it seems, drug companies should finally dare to hold themselves accountable.
